News

MRNA's second-quarter results are likely to spotlight a sharp decline in Spikevax sales, RSV uptake and key pipeline ...
Earlier this summer the FDA asked Moderna for more efficacy data on its flu vaccine before it could review an mRNA-based ...
Compared to the standard shot, the mRNA vaccine had an overall vaccine efficacy that was 26.6 percent higher, and 27.4 ...
Moderna stock rises on flu vaccine data and FDA approvals, while healthcare stocks remain under pressure amid political ...
Back in early 2022, Moderna said it was planning to have a combination COVID and flu vaccine ready by the fall of 2023. Many months later, it's still not clear when the public will have access to ...
Moderna, already in cash-saving mode amid uncertain vaccine dynamics, is backing off from its plans to construct an mRNA drug ...
Moderna’s vaccine remains stable at -20°C, the temperature of a household freezer, for up to six months. It can remain refrigerated at 4°C for up to 30 days.
Moderna says its new bivalent vaccine is its "lead candidate for a Fall 2022 booster." Here, a vial of the company's COVID-19 vaccine sits on a table at a vaccination clinic in San Rafael, ...
Moderna's Covid-19 vaccine is safe and highly effective in children ages 12 to 17, the company said Tuesday. It would be the second Covid-19 vaccine available for the age group if it is ...
Moderna’s Covid-19 vaccine is an mRNA vaccine that relies on messenger RNA to deliver instructions to the cells in your body, which then produce small parts of the Covid-19 virus that are just ...
The race to develop effective cancer vaccines has entered a new phase, with late-stage trials from companies like Moderna ...